TNFAIP3 is an inhibitor of NF-κB that was reported to reduce airway leukocyte recruitment, peribronchoalveolar inflammation and mucus production and airway hyperresponsiveness (AHR) in mice subjected to OVA sensitization/challenge [49,50]. The gene discussed is NFKB1; the disease is airway hyperresponsiveness.